Pharmaceutical News

RSS

Combination therapy for severe depression

Severe depression is life threatening. So it is worth every effort to get depression under control and make life more manageable. For most people, that means some combination of antidepressant drugs and talk therapy.

29 Jun 2010

Health Canada recommends new pneumococcal vaccine for young children

In December, 2009, Health Canada approved a new vaccine for children aged six weeks through five years to prevent infections caused by the bacteria called pneumococcus or Streptococcus.

29 Jun 2010

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

Results of a new study demonstrated that initial combination therapy with Welchol® (colesevelam HCl) 3.75 g/d and metformin (initiated at 850 mg/d; uptitrated to 1700 mg/d thereafter) significantly improved glycemic and lipid control in drug-naive adult type 2 diabetes patients with high LDL cholesterol (LDL-C).

29 Jun 2010

FDA approves Teva's generic Effexor XR antidepressant

Teva Pharmaceutical Industries Ltd. announced today U.S. Food and Drug Administration (FDA) approval of Venlafaxine HCl ER Capsules, the Company's generic version of Wyeth's antidepressant Effexor XR®. Shipment is expected to commence on July 1, 2010, as per the terms of the 2006 agreement with Wyeth.

29 Jun 2010

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

A new study published online today by JAMA shows that among patients age 65 years and older, rosiglitazone (a medication for treating Type 2 diabetes) is associated with an increased risk of stroke, heart failure, and all-cause mortality (death) when compared with pioglitazone (another medication for diabetes). The study was published online today in advance of an upcoming Food and Drug Administration meeting that will review the safety of rosiglitazone. The paper will appear in the July 28 print issue of JAMA.

29 Jun 2010

APP to market Anastrozole 1 mg tablets in U.S.

Fresenius Kabi Pharmaceuticals Holding, Inc., announced today that APP Pharmaceuticals will immediately begin marketing Anastrozole tablets in the U.S., after the U.S. Food and Drug Administration granted approval to market the breast cancer treatment medication to Fresenius Kabi Oncology Limited.

29 Jun 2010

EpiCept requests FDA priority review of Ceplene NDA for AML

EpiCept Corporation announced today that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Ceplene® (histamine dihydrochloride). EpiCept is seeking approval for Ceplene, administered concomitantly with low-dose interleukin-2 (IL-2), for the remission maintenance and prevention of relapse in patients with Acute Myeloid Leukemia (AML) in first complete remission.

29 Jun 2010

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Depomed, Inc. today announced that it has received a $10 million milestone payment from Abbott Products, Inc., its licensee of DM-1796, for the U.S. Food and Drug Administration's acceptance for filing of the New Drug Application (NDA) for DM-1796 for the management of postherpetic neuralgia (PHN), or pain after shingles.

29 Jun 2010

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

A two-year effort aimed at preventing the emergence of drug-resistant malaria near the border between Cambodia and Thailand is showing signs of success, Duong Socheat, head of Cambodia's National Center for Malaria Control, said on Friday, DPA/Earth Times reports.

29 Jun 2010

Ahead of International AIDS Conference, health experts call for scientifically-based drug policies

Ahead of the International AIDS Conference, scheduled to kick off July 18, health experts on Monday called for a rethinking of international drug policies to incorporate greater scientific evidence and increase access to HIV prevention, treatment and care, the Associated Press reports (6/28).

29 Jun 2010

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

Sunridge International, announced today that it has completed production and delivery of 60 PNT Units and 10,000 disposable rings to its exclusive distributor, Beijing Vision World Trading Company (BV) of China.

28 Jun 2010

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

Tarix Pharmaceuticals today announced that it's drug, TXA127, has been granted Orphan Drug designation from the U.S. Food and Drug Administration (FDA) as a treatment to enhance engraftment in patients receiving a stem cell transplant. TXA127 has also received Orphan Drug designation for the treatment of Myelodysplastic Syndrome (MDS).

28 Jun 2010

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

ULURU Inc. announced today that Strakan International Limited and ULURU have divested their respective interest in Zindaclin® to a subsidiary of Crawford Healthcare Limited, a pharmaceutical company based in England. Zindaclin® is a product for the treatment of acne which is outside the strategic focus of ULURU. This product was included in the technology package ULURU acquired when it was formed in 2005.

28 Jun 2010

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Marinomed Biotechnologie GmbH, a company focused on the development of innovative therapies for respiratory diseases, announced today that it has signed a licensing agreement with the international pharmaceutical company Boehringer Ingelheim. The deal will aim to further extend marketing of Marinomed's anti-viral nasal spray for the treatment of the Common Cold to all of Europe (except Austria and UK), Russia and CIS, South America, parts of Asia and Australia.

28 Jun 2010

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Pain Therapeutics, Inc. announced today a modification of its strategic alliance with King Pharmaceuticals, Inc. for REMOXY outside the U.S. The move signals a desire to target Europe's small and growing market for strong pain medications.

28 Jun 2010

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Boston Therapeutics, Inc. has announced that it has submitted structure and function claims of its SUGARDOWN™ to the US Food and Drug Administration on June 21, 2010.

28 Jun 2010

Aestus Therapeutics announces license agreement with Astellas Pharma

Aestus Therapeutics, Inc. announced today a license agreement with Astellas Pharma Inc. (Astellas; Tokyo, Japan) to provide Aestus with exclusive, world-wide rights to the Astellas product FK614. Aestus will develop the product as ATx08-001, a novel, first-in-class therapeutic for the treatment of neuropathic pain. The first clinical trial will start later this year.

28 Jun 2010

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

Merck and Cardiome Pharma Corp. today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended marketing approval for BRINAVESS® (vernakalant), an investigational intravenous (IV) formulation for the conversion of recent onset atrial fibrillation (AF) to sinus rhythm in adults.

28 Jun 2010

AHF rejects Obama trial balloon of $30M for nation's ADAP

AIDS Healthcare Foundation, the largest global AIDS organization, is rejecting a trial balloon floated by Obama Administration officials that suggests $30 million in additional funding could adequately help close a gaping $126 million hole in funding for the nation's AIDS Drug Assistance Program, the federal and state funded, state run network of assistance programs that supply lifesaving AIDS drugs to low-income Americans in need.

28 Jun 2010

Merck challenges New York jury decision in federal FOSAMAX retrial

Merck & Co., Inc. today said it is challenging the decision returned by a New York jury in the retrial of a federal FOSAMAX case, Boles v. Merck. This case was the Plaintiffs' Steering Committee's top choice to take to trial and involved a Florida woman who blamed her dental and jaw problems on FOSAMAX. The first case to reach a verdict, Maley v. Merck, resulted in a defense verdict for Merck on May 5, 2010.

28 Jun 2010

Pharmaceutical News

Combination therapy for severe depression

Health Canada recommends new pneumococcal vaccine for young children

Welchol plus metformin combination therapy reduces A1C, LDL-C levels in type 2 diabetes patients

FDA approves Teva's generic Effexor XR antidepressant

Rosiglitazone associated with increased risk of serious cardiovascular events compared with pioglitazone

APP to market Anastrozole 1 mg tablets in U.S.

EpiCept requests FDA priority review of Ceplene NDA for AML

FDA's acceptance for filing of DM-1796 NDA triggers $10M milestone payment to Depomed

Efforts to contain drug-resistant malaria near Thai-Cambodian border appear to be working, officials say

Ahead of International AIDS Conference, health experts call for scientifically-based drug policies

Sunridge International delivers 60 PNT Units and 10,000 disposable rings to BV of China

FDA grants Tarix's TXA127 Orphan Drug designation for stem cell engraftment and treatment of MDS

ULURU, Strakan International divest interest in Zindaclin to Crawford Healthcare subsidiary

Marinomed, Boehringer Ingelheim sign licensing agreement for common cold anti-viral nasal spray

Pain Therapeutics modifies strategic alliance with King Pharmaceuticals for REMOXY outside U.S.

Boston Therapeutics submits structure, function claims of SUGARDOWN to FDA

Aestus Therapeutics announces license agreement with Astellas Pharma

EMA CHMP recommends marketing approval of BRINAVESS for conversion of recent onset AF to sinus rhythm

AHF rejects Obama trial balloon of $30M for nation's ADAP

Merck challenges New York jury decision in federal FOSAMAX retrial

Real-time Raman monitoring for pharmaceutical hot melt extrusion

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

Latest News